Autopsy report · NCT00325572

Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism

“Lack of efficacy to proceed to Phase 2”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 5 years 1 month before it stopped.
• 89 participants enrolled.
• Results were posted on the registry 7 years 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Milton S. Hershey Medical Center

Sponsor type

University, hospital or other

Conditions

Autism; Pervasive Developmental Disorder

Interventions

oral zinc and vitamin C supplements; oral Placebo

Participants

89

Sites

1

Countries

United States

Trials that died the same way

• Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
  “The study was terminated based on review of Phase 2 efficacy data” (72% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (71% match in meaning)
• A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
  “Lack of efficacy” (68% match in meaning)
• A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
  “Due to safety findings in ongoing Phase 2 trials.” (67% match in meaning)
• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.